Clinical and Genetic Markers of Vascular Toxicity in Glioblastoma Patients: Insights from NRG Oncology RTOG-0825 Academic Background Glioblastoma (GBM) is a highly aggressive form of brain cancer, accounting for nearly 80% of malignant primary brain tumors. Despite standard treatments including surgical resection, radiotherapy, and chemotherapy, th...

The Relationship Between Metabolic Reprogramming and Glutamine Metabolism in Glioblastoma Background Introduction Glioblastoma is a highly aggressive primary brain tumor with a very poor prognosis. Although current standard treatments include surgery, radiotherapy, and chemotherapy, there is no cure for the disease. In recent years, metabolic repro...

The Impact of Glioblastoma Differentiation on Blood-Brain Barrier Permeability Background Introduction Glioblastoma Multiforme (GBM) is a highly aggressive brain tumor, and its treatment is extremely challenging due to its complex biological characteristics and the presence of the Blood-Brain Barrier (BBB). The BBB is a complex structure composed o...

Background Glioblastoma (GBM) is a highly aggressive central nervous system malignancy with very poor prognosis, typically associated with short patient survival. Although significant advancements have been made in tumor treatment technologies and strategies in recent years, traditional radiotherapy and chemotherapy still struggle to achieve satisf...

The Role of the Novel Circular RNA circZEB1 in the Malignant Phenotype of Glioblastoma Stem Cells and Its Molecular Mechanism Research Background Glioblastoma (GBM) is one of the most aggressive and fatal primary tumors in the central nervous system, with a very poor prognosis for patients. Even with surgery, radiotherapy, and chemotherapy, the ave...